 Difference mortality patients captopril enalapril Xamoterol Severe Heart Failure Study double-blind placebo-controlled multinational trial Xamoterol Severe Heart Failure patients captopril enalapril end follow-up period cumulative probability survival patients coronary artery disease cardiomyopathy captopril group enalapril group excess mortality captopril group indexes severity heart failure baseline exercise duration functional class cardiothoracic ratio ejection fraction dose diuretic drugs excess mortality subsets patients countries Examination regimen insufficient daily dosage captopril inadequate schedule administration responsible different degrees angiotensin-converting enzyme inhibition enalapril captopril groups hence difference mortality important future clinical trials complete circadian angiotensin-converting enzyme inhibition necessary full benefit therapy heart failure